ProQR Therapeutics N.V.
PRQR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001612940
In the last 90 days, ProQR Therapeutics N.V. insiders filed 4 open-market purchases and 0 sales; 70 institutions reported holding it in 13F filings for Q2 2026, worth $113.0M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding ProQR Therapeutics N.V. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 51 | 46 | −5 |
| Shares | 21.1M | 18.7M | −2.42M (−11.4%) |
| Value | $34.2M | $24.3M | −$9.91M (−28.9%) |
New holders (4)
Institutions that held ProQR Therapeutics N.V. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 40,610 | $52.8K | 0.00% |
| Flaharty Asset Management, LLC | 2,000 | $2.60K | 0.00% |
| Geneos Wealth Management Inc. | 1,000 | $1.30K | 0.00% |
| Qube Research & Technologies Ltd | 33 | $43 | 0.00% |
Sold out (9)
Institutions that held ProQR Therapeutics N.V. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Opaleye Management Inc. | 653,000 | $1.06M |
| Deutsche Bank AG | 385,208 | $624.0K |
| Renaissance Technologies LLC | 200,499 | $325.0K |
| Citadel Advisors LLC | 116,792 | $189.2K |
| Centiva Capital, LP | 23,160 | $37.5K |
| HRT Financial LP | 21,494 | $34.0K |
| Raymond James & Associates | 20,550 | $33.3K |
| XTX Topco Ltd | 16,405 | $26.6K |
| GWM Advisors LLC | 200 | $324 |